Half-dose for Halcygen
Tuesday, 07 October, 2008
Halcygen Pharmaceuticals (ASX: HGN) has demonstrated the effectiveness of the company's SUBA-itraconazole antifungal in a recent pharmacokinetic trial.
The trial was the first of three pharmacokinetic studies the company is conducting for the Investigational New Drug [IND] application recently approved by the FDA.
Halcygen was able to prove that SUBA-itraconazole in a 'half-dose' format gives comparable pharmacokinetic levels to a full dose of itraconazole market leader Sporanox.
All three pharmacokinetic trials should be complete by the end of the year.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
